Evaluation in a Cytokine Storm Model in Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells)

Lapuente, J. P. ; Gómez, G. ; Marco-Brualla, J. ; Fernández, P. ; Desportes, P. ; Sanz, J. ; García-Gil, M. ; Bermejo, F. ; Martín, J. V. S. ; Algaba, A. ; De Gregorio, J. C. ; Lapuente, D. ; De Gregorio, A. ; Lapuente, B. ; Gómez, S. ; de las Viñas Andrés, M. ; Anel Bernal, A. (Universidad de Zaragoza)

Resumen: Our research group has been developing a series of biological drugs produced by cocul-ture techniques with M2-polarized macrophages with different primary tissue cells and/or mesen-chymal stromal cells (MSC), generally from fat, to produce anti-inflammatory and anti-fibrotic ef-fects, avoiding the overexpression of pro-inflammatory cytokines by the innate immune system at a given time. One of these products is the drug PRS CK STORM, a medium conditioned by allogenic M2-polarized macrophages, from coculture, with those macrophages M2 with MSC from fat, whose composition, in vitro safety, and efficacy we studied. In the present work, we publish the results obtained in terms of safety (pharmacodynamics and pharmacokinetics) and efficacy of the intravenous application of this biological drug in a murine model of cytokine storm associated with severe infectious processes, including those associated with COVID-19. The results demonstrate the safety and high efficacy of PRS CK STORM as an intravenous drug to prevent and treat the cytokine storm associated with infectious processes, including COVID-19.

Idioma: Inglés

DOI: 10.3390/biomedicines10051094

Año: 2022

Publicado en: Biomedicines 10, 5 (2022), 1094 [27 pp]
ISSN: 2227-9059

Factor impacto JCR: 4.7 (2022)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 68 / 278 = 0.245 (2022) - Q1 - T1
Categ. JCR: BIOCHEMISTRY & MOLECULAR BIOLOGY rank: 92 / 285 = 0.323 (2022) - Q2 - T1
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 54 / 136 = 0.397 (2022) - Q2 - T2

Factor impacto CITESCORE: 3.7 - Medicine (Q2) - Biochemistry, Genetics and Molecular Biology (Q3)

Factor impacto SCIMAGO: 0.897 - Medicine (miscellaneous) (Q1) - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q2)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B31-20R

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)